Lazard Asset Management
NAGE

Lazard Asset Management’s Niagen Bioscience NAGE Stock Holding History

Lazard Asset Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-96,359
Closed -$613K – 2120
2025
Q4 		$613K Buy
96,359
+69,093
+253% +$481K ﹤0.01% 1312
2025
Q3 		$254K Sell
27,266
-189,446
-87% -$1.91M ﹤0.01% 1533
2025
Q2 		$3.12M Buy
216,712
+12,314
+6% +$122K ﹤0.01% 866
2025
Q1 		$1.41M Buy
204,398
+172,712
+545% +$1.09M ﹤0.01% 1080
2024
Q4 		$168K Buy
31,686
+14,784
+87% +$80.9K ﹤0.01% 1657
2024
Q3 		$61K Buy
+16,902
New +$53.2K ﹤0.01% 1885
2024
Q2 		– Sell
-12,592
Closed -$43K – 2461
2024
Q1 		$43K Buy
+12,592
New +$23.3K ﹤0.01% 1748

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Lazard Asset Management's NAGE Position: Q1 2026 in Review

Lazard Asset Management sold out of Niagen Bioscience (NAGE) in Q1 2026, closing a stake of 96,359 shares — an estimated $613K sold.

Lazard Asset Management first reported a position in NAGE in Q1 2024 and held it in 7 quarters. The position peaked at $3.12M in Q2 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • Lazard Asset Management reported no remaining Niagen Bioscience position as of Q1 2026 after selling out during the quarter.
  • Lazard Asset Management sold 96,359 Niagen Bioscience shares in Q1 2026, an estimated $613K.
  • Lazard Asset Management first reported a position in Niagen Bioscience in Q1 2024 and held it in 7 quarters.
  • Lazard Asset Management's Niagen Bioscience position peaked at $3.12M in Q2 2025.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.